What was Boston Scientific's overall financial performance in 2016?

In 2016, Boston Scientific reported a 12% increase in net sales, reaching $8.386 billion. The company experienced a net income of $347 million ($0.25 per diluted share). While revenue showed robust growth, reported net income was significantly impacted by substantial litigation-related charges.

Which business segments performed particularly well in 2016?

The Urology and Pelvic Health segment saw the most significant growth with a 45% increase in net sales, largely driven by strategic acquisitions. The Interventional Cardiology segment also performed strongly, with a 12% increase in net sales, supported by key products like drug-eluting stents and structural heart devices.

What are the main risk factors identified by Boston Scientific for 2017?

Key risks highlighted include intense competition and the rapid pace of technological change in the medical device industry, potential declines in market size and average selling prices, healthcare cost containment pressures and regulatory reforms, and the successful integration of acquired businesses. Significant litigation and potential regulatory actions also remain a concern.

How did acquisitions contribute to Boston Scientific's 2016 results?

Acquisitions were a significant driver of growth in 2016. Notable acquisitions included the AMS Portfolio (Urology and Pelvic Health), EndoChoice (Endoscopy), and Cosman Medical (Neuromodulation), which contributed substantial net sales and expanded the company's product portfolios and market reach.

BSX 10-K FY2016 Annual Report — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation (BSX) reported significant net sales growth of 12% in 2016, reaching $8.386 billion. This growth was driven by strong performance across its key business segments, notably Urology and Pelvic Health (45% increase, bolstered by acquisitions) and Interventional Cardiology (12% increase, driven by drug-eluting stents and structural heart products). The company's strategic focus on innovation and market expansion appears to be yielding positive financial results, with adjusted net income showing a substantial increase. However, the report also highlights significant litigation-related charges, particularly from transvaginal surgical mesh cases, which impacted reported net income. The company continues to invest heavily in research and development, underscoring its commitment to future growth through new product introductions and technological advancements. Despite facing competitive pressures and regulatory complexities inherent in the medical device industry, Boston Scientific demonstrated solid operational execution and revenue generation in 2016.

Financial Highlights

53 data points

Beta

Revenue

$8.39B

0.7% Gross Margin

Net Income

$347.00M

0.0% Net Margin

EPS (Diluted)

$0.25

Total Assets

$18.10B

Cash & Equivalents

$196.00M

Free Cash Flow

$806.00M

Financial Statements

Beta

Revenue	$8.39B
Cost of Revenue	$2.42B
Gross Profit	$5.96B
SG&A Expenses	$3.10B
Operating Expenses	$5.51B
Operating Income	$447.00M
Interest Expense	$233.00M
Net Income	$347.00M
EPS (Basic)	$0.26
EPS (Diluted)	$0.25
Shares Outstanding (Basic)	1.36B
Shares Outstanding (Diluted)	1.38B

Key Highlights

1Net sales increased by 12% to $8.386 billion in 2016, driven by strong performance across most business segments.
2Urology and Pelvic Health segment experienced a significant 45% sales increase, largely due to acquisitions.
3Interventional Cardiology sales grew 12%, supported by drug-eluting stents and structural heart devices like the WATCHMAN and Lotus valve systems.
4Reported net income was $347 million ($0.25 per diluted share), but significant litigation-related charges ($804 million pre-tax) impacted profitability.
5Research and Development expenses increased by 5% to $920 million, reflecting continued investment in innovation.
6The company generated $972 million in cash from operating activities, a substantial increase from the prior year.
7Acquisitions played a key role in growth, with notable additions including AMS Portfolio, EndoChoice, and Cosman Medical.

BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2016

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions